Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Endothelial tip cells in vitro are less glycolytic and have a more flexible response to metabolic stress than non-tip cells.

Yetkin-Arik B, Vogels IMC, Neyazi N, van Duinen V, Houtkooper RH, van Noorden CJF, Klaassen I, Schlingemann RO.

Sci Rep. 2019 Jul 18;9(1):10414. doi: 10.1038/s41598-019-46503-2.

2.

Central serous chorioretinopathy: Towards an evidence-based treatment guideline.

van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TYY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF.

Prog Retin Eye Res. 2019 Jul 15. pii: S1350-9462(18)30094-6. doi: 10.1016/j.preteyeres.2019.07.003. [Epub ahead of print] Review.

3.

Quality factor based correction for SD-OCT measurements in cataract patients.

Darma S, van den Berg TJTP, Kok PHB, Hulsman CA, Mourits MP, Schlingemann RO, Verbraak FD.

Acta Ophthalmol. 2019 Jun 18. doi: 10.1111/aos.14153. [Epub ahead of print]

PMID:
31210009
4.

Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration.

Schmid MK, Thiel MA, Lienhard K, Schlingemann RO, Faes L, Bachmann LM.

Eye (Lond). 2019 May 1. doi: 10.1038/s41433-019-0455-6. [Epub ahead of print]

PMID:
31043690
5.

Test performance of optical coherence tomography angiography in detecting retinal diseases: a systematic review and meta-analysis.

Faes L, Bodmer NS, Locher S, Keane PA, Balaskas K, Bachmann LM, Schlingemann RO, Schmid MK.

Eye (Lond). 2019 Aug;33(8):1327-1338. doi: 10.1038/s41433-019-0421-3. Epub 2019 Apr 10.

PMID:
30971815
6.

Diagnostic Accuracy of a Device for the Automated Detection of Diabetic Retinopathy in a Primary Care Setting.

Verbraak FD, Abramoff MD, Bausch GCF, Klaver C, Nijpels G, Schlingemann RO, van der Heijden AA.

Diabetes Care. 2019 Apr;42(4):651-656. doi: 10.2337/dc18-0148. Epub 2019 Feb 14.

PMID:
30765436
7.

Expression patterns of endothelial permeability pathways in the development of the blood-retinal barrier in mice.

van der Wijk AE, Wisniewska-Kruk J, Vogels IMC, van Veen HA, Ip WF, van der Wel NN, van Noorden CJF, Schlingemann RO, Klaassen I.

FASEB J. 2019 Apr;33(4):5320-5333. doi: 10.1096/fj.201801499RRR. Epub 2019 Jan 30.

8.

Long Survival and Preservation of Good Visual Acuity in a Patient with Bilateral Diffuse Uveal Melanocytic Proliferation.

van Noort BC, Keunen JEE, Schlingemann RO, Marinkovic M.

Ocul Oncol Pathol. 2019 Jan;5(1):75-78. doi: 10.1159/000488454. Epub 2018 Jun 19.

9.

The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases.

Van Bergen T, Etienne I, Cunningham F, Moons L, Schlingemann RO, Feyen JHM, Stitt AW.

Prog Retin Eye Res. 2019 Mar;69:116-136. doi: 10.1016/j.preteyeres.2018.10.006. Epub 2018 Oct 30. Review.

PMID:
30385175
10.
11.

Glucocorticoids exert differential effects on the endothelium in an in vitro model of the blood-retinal barrier.

van der Wijk AE, Canning P, van Heijningen RP, Vogels IMC, van Noorden CJF, Klaassen I, Schlingemann RO.

Acta Ophthalmol. 2019 Mar;97(2):214-224. doi: 10.1111/aos.13909. Epub 2018 Aug 31.

PMID:
30168271
12.

IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers.

Dallinga MG, Yetkin-Arik B, Kayser RP, Vogels IMC, Nowak-Sliwinska P, Griffioen AW, van Noorden CJF, Klaassen I, Schlingemann RO.

Angiogenesis. 2018 Nov;21(4):823-836. doi: 10.1007/s10456-018-9627-4. Epub 2018 Jun 27.

13.

Spatial and temporal recruitment of the neurovascular unit during development of the mouse blood-retinal barrier.

van der Wijk AE, Vogels IMC, van Veen HA, van Noorden CJF, Schlingemann RO, Klaassen I.

Tissue Cell. 2018 Jun;52:42-50. doi: 10.1016/j.tice.2018.03.010. Epub 2018 Mar 23.

14.

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

Lorés-Motta L, Riaz M, Grunin M, Corominas J, van Asten F, Pauper M, Leenders M, Richardson AJ, Muether P, Cree AJ, Griffiths HL, Pham C, Belanger MC, Meester-Smoor MA, Ali M, Heid IM, Fritsche LG, Chakravarthy U, Gale R, McKibbin M, Inglehearn CF, Schlingemann RO, Omar A, Chen J, Koenekoop RK, Fauser S, Guymer RH, Hoyng CB, de Jong EK, Lotery AJ, Mitchell P, den Hollander AI, Baird PN, Chowers I.

JAMA Ophthalmol. 2018 Aug 1;136(8):875-884. doi: 10.1001/jamaophthalmol.2018.2019.

15.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 Aug;21(3):425-532. doi: 10.1007/s10456-018-9613-x. Review.

16.

Involvement of the ubiquitin-proteasome system in the expression of extracellular matrix genes in retinal pigment epithelial cells.

Ramos de Carvalho JE, Verwoert MT, Vogels IMC, Reits EA, Van Noorden CJF, Klaassen I, Schlingemann RO.

Biochem Biophys Rep. 2018 Jan 28;13:83-92. doi: 10.1016/j.bbrep.2018.01.005. eCollection 2018 Mar.

17.

Antiplatelet and Anticoagulant Drugs Do Not Affect Visual Outcome in Neovascular Age-Related Macular Degeneration in the BRAMD Trial.

Buitendijk GHS, Schauwvlieghe AME, Vingerling JR, Schlingemann RO, Klaver CCW; comparing Bevacizumab to Ranibizumab in Age-related macular degeneration (BRAMD) Trial Research Group.

Am J Ophthalmol. 2018 Mar;187:130-137. doi: 10.1016/j.ajo.2018.01.003. Epub 2018 Jan 9.

PMID:
29330064
18.

Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes.

Klaassen I, de Vries EW, Vogels IMC, van Kampen AHC, Bosscha MI, Steel DHW, Van Noorden CJF, Lesnik-Oberstein SY, Schlingemann RO.

PLoS One. 2017 Nov 2;12(11):e0187304. doi: 10.1371/journal.pone.0187304. eCollection 2017.

19.

Modulation of the Proteasome Pathway by Nano-Curcumin and Curcumin in Retinal Pigment Epithelial Cells.

Ramos de Carvalho JE, Verwoert MT, Vogels IMC, Schipper-Krom S, Van Noorden CJF, Reits EA, Klaassen I, Schlingemann RO.

Ophthalmic Res. 2018;59(2):98-109. doi: 10.1159/000481261. Epub 2017 Oct 27.

PMID:
29073609
20.

Stem Cell Derived Retinal Pigment Epithelium: The Role of Pigmentation as Maturation Marker and Gene Expression Profile Comparison with Human Endogenous Retinal Pigment Epithelium.

Bennis A, Jacobs JG, Catsburg LAE, Ten Brink JB, Koster C, Schlingemann RO, van Meurs J, Gorgels TGMF, Moerland PD, Heine VM, Bergen AA.

Stem Cell Rev. 2017 Oct;13(5):659-669. doi: 10.1007/s12015-017-9754-0.

21.

Is leukostasis a crucial step or epiphenomenon in the pathogenesis of diabetic retinopathy?

van der Wijk AE, Hughes JM, Klaassen I, Van Noorden CJF, Schlingemann RO.

J Leukoc Biol. 2017 Oct;102(4):993-1001. doi: 10.1189/jlb.3RU0417-139. Epub 2017 Jul 19. Review.

PMID:
28724696
22.

TNFα-Induced Disruption of the Blood-Retinal Barrier In Vitro Is Regulated by Intracellular 3',5'-Cyclic Adenosine Monophosphate Levels.

van der Wijk AE, Vogels IMC, van Noorden CJF, Klaassen I, Schlingemann RO.

Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3496-3505. doi: 10.1167/iovs.16-21091.

PMID:
28715583
23.

PREDICTIVE VALUE OF OPTICAL COHERENCE TOMOGRAPHIC FEATURES IN THE BEVACIZUMAB AND RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA (BRDME) STUDY.

Fickweiler W, Schauwvlieghe AME, Schlingemann RO, Maria Hooymans JM, Los LI, Verbraak FD; BRDME Research Group.

Retina. 2018 Apr;38(4):812-819. doi: 10.1097/IAE.0000000000001626.

PMID:
28406860
24.

Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome.

Ramos de Carvalho JE, Schlingemann RO, Oranje M, Bemelman FJ, van Schooneveld MJ.

Int Ophthalmol. 2018 Feb;38(1):399-407. doi: 10.1007/s10792-017-0470-1. Epub 2017 Mar 8.

25.

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome.

Chung WH, van Dijk EH, Mohabati D, Dijkman G, Yzer S, de Jong EK, Fauser S, Schlingemann RO, Hoyng CB, Boon CJ.

Clin Ophthalmol. 2016 Dec 21;11:63-70. doi: 10.2147/OPTH.S122568. eCollection 2017.

26.

Correction: CD34 Promotes Pathological Epi-Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.

Siemerink MJ, Hughes MR, Dallinga MG, Gora T, Cait J, Vogels IM, Yetkin-Arik B, Van Noorden CJ, Klaassen I, McNagny KM, Schlingemann RO.

PLoS One. 2016 Dec 21;11(12):e0169061. doi: 10.1371/journal.pone.0169061. eCollection 2016.

27.
28.

Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.

Fickweiler W, Klaassen I, Vogels IM, Hooymans JM, Wolffenbuttel BH, Los LI, Schlingemann RO; BRDME Research Group.

Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6234-6241. doi: 10.1167/iovs.16-20157.

PMID:
27842163
29.

Computational Screening of Tip and Stalk Cell Behavior Proposes a Role for Apelin Signaling in Sprout Progression.

Palm MM, Dallinga MG, van Dijk E, Klaassen I, Schlingemann RO, Merks RM.

PLoS One. 2016 Nov 9;11(11):e0159478. doi: 10.1371/journal.pone.0159478. eCollection 2016.

30.

CD34 Promotes Pathological Epi-Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.

Siemerink MJ, Hughes MR, Dallinga MG, Gora T, Cait J, Vogels IM, Yetin-Arik B, Van Noorden CJ, Klaassen I, McNagny KM, Schlingemann RO.

PLoS One. 2016 Jun 28;11(6):e0157902. doi: 10.1371/journal.pone.0157902. eCollection 2016. Erratum in: PLoS One. 2016 Dec 21;11(12 ):e0169061.

31.

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study.

Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO.

PLoS One. 2016 May 20;11(5):e0153052. doi: 10.1371/journal.pone.0153052. eCollection 2016.

32.

Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intra-vitreal injection.

Lapid-Gortzak R, Traversari R, van der Linden JW, Lesnik Oberstein SY, Lapid O, Schlingemann RO.

Int Ophthalmol. 2017 Feb;37(1):131-137. doi: 10.1007/s10792-016-0236-1. Epub 2016 Apr 30.

33.

Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus.

Sohn EH, van Dijk HW, Jiao C, Kok PH, Jeong W, Demirkaya N, Garmager A, Wit F, Kucukevcilioglu M, van Velthoven ME, DeVries JH, Mullins RF, Kuehn MH, Schlingemann RO, Sonka M, Verbraak FD, Abràmoff MD.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2655-64. doi: 10.1073/pnas.1522014113. Epub 2016 Apr 25.

34.

HIV-Associated Neuroretinal Disorder in Patients With Well-Suppressed HIV-Infection: A Comparative Cohort Study.

Demirkaya N, Wit FW, van Den Berg TJ, Kooij KW, Prins M, Schlingemann RO, Abramoff MD, Reiss P, Verbraak FD; AGEhIV Cohort Study Group.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1388-97. doi: 10.1167/iovs.15-18537.

PMID:
27018841
35.

Plasmalemma Vesicle-Associated Protein Has a Key Role in Blood-Retinal Barrier Loss.

Wisniewska-Kruk J, van der Wijk AE, van Veen HA, Gorgels TG, Vogels IM, Versteeg D, Van Noorden CJ, Schlingemann RO, Klaassen I.

Am J Pathol. 2016 Apr;186(4):1044-54. doi: 10.1016/j.ajpath.2015.11.019. Epub 2016 Feb 12.

PMID:
26878208
36.

Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study).

Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Van Leeuwen R, Vingerling JR, Moll AC, Schlingemann RO.

BMC Ophthalmol. 2015 Jul 7;15:71. doi: 10.1186/s12886-015-0043-x.

37.

Retinal Structure and Function in Perinatally HIV-Infected and cART-Treated Children: A Matched Case-Control Study.

Demirkaya N, Cohen S, Wit FW, Abramoff MD, Schlingemann RO, Kuijpers TW, Reiss P, Pajkrt D, Verbraak FD.

Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3945-54. doi: 10.1167/iovs.15-16855.

PMID:
26087360
38.

Detecting signs of retinal leakage in exudative AMD using Cirrus OCT versus SL SCAN-1, a novel integrated FD-OCT into a common slit lamp.

Stehouwer M, Verbraak FD, Schlingemann RO, van Leeuwen TG.

Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):37-41. doi: 10.1007/s00417-015-2997-z. Epub 2015 Apr 23.

39.

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga M, Shen L, Schlingemann RO, Pili R, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P.

Angiogenesis. 2015 Jul;18(3):233-44. doi: 10.1007/s10456-015-9462-9. Epub 2015 Apr 1.

40.

The role of CTGF in diabetic retinopathy.

Klaassen I, van Geest RJ, Kuiper EJ, van Noorden CJ, Schlingemann RO.

Exp Eye Res. 2015 Apr;133:37-48. doi: 10.1016/j.exer.2014.10.016. Review.

PMID:
25819453
41.

Optical density filters modeling media opacities cause decreased SD-OCT retinal layer thickness measurements with inter- and intra-individual variation.

Darma S, Kok PH, van den Berg TJ, Abràmoff MD, Faber DJ, Hulsman CA, Zantvoord F, Mourits MP, Schlingemann RO, Verbraak FD.

Acta Ophthalmol. 2015 Jun;93(4):355-61. doi: 10.1111/aos.12596. Epub 2014 Dec 8.

42.

The RD5000 database: facilitating clinical, genetic, and therapeutic studies on inherited retinal diseases.

van Huet RA, Oomen CJ, Plomp AS, van Genderen MM, Klevering BJ, Schlingemann RO, Klaver CC, van den Born LI, Cremers FP; RD5000 Study Group.

Invest Ophthalmol Vis Sci. 2014 Nov 17;55(11):7355-60. doi: 10.1167/iovs.14-15317. Review.

PMID:
25404643
43.

NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis.

Noort AR, van Zoest KP, Weijers EM, Koolwijk P, Maracle CX, Novack DV, Siemerink MJ, Schlingemann RO, Tak PP, Tas SW.

J Pathol. 2014 Nov;234(3):375-85. doi: 10.1002/path.4403. Epub 2014 Aug 28.

44.

Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy.

Wisniewska-Kruk J, Klaassen I, Vogels IM, Magno AL, Lai CM, Van Noorden CJ, Schlingemann RO, Rakoczy EP.

Exp Eye Res. 2014 May;122:123-31. doi: 10.1016/j.exer.2014.03.005. Epub 2014 Apr 3.

PMID:
24703908
45.

Orthogonal polarization spectral imaging of conjunctival microcirculation.

van Zijderveld R, Ince C, Schlingemann RO.

Graefes Arch Clin Exp Ophthalmol. 2014 May;252(5):773-9. doi: 10.1007/s00417-014-2603-9. Epub 2014 Mar 14.

PMID:
24627137
46.

Recent advances in ophthalmic molecular imaging.

Ramos de Carvalho JE, Verbraak FD, Aalders MC, van Noorden CJ, Schlingemann RO.

Surv Ophthalmol. 2014 Jul-Aug;59(4):393-413. doi: 10.1016/j.survophthal.2013.09.005. Epub 2013 Oct 3. Review.

PMID:
24529711
47.

Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.

Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P; RESTORE Extension Study Group.

Ophthalmology. 2014 May;121(5):1045-53. doi: 10.1016/j.ophtha.2013.11.041. Epub 2014 Feb 1.

48.

Connective tissue growth factor is involved in structural retinal vascular changes in long-term experimental diabetes.

Van Geest RJ, Leeuwis JW, Dendooven A, Pfister F, Bosch K, Hoeben KA, Vogels IM, Van der Giezen DM, Dietrich N, Hammes HP, Goldschmeding R, Klaassen I, Van Noorden CJ, Schlingemann RO.

J Histochem Cytochem. 2014 Feb;62(2):109-18. doi: 10.1369/0022155413512656. Epub 2013 Nov 11.

49.

Complement factor C3a alters proteasome function in human RPE cells and in an animal model of age-related RPE degeneration.

Ramos de Carvalho JE, Klaassen I, Vogels IM, Schipper-Krom S, van Noorden CJ, Reits E, Gorgels TG, Bergen AA, Schlingemann RO.

Invest Ophthalmol Vis Sci. 2013 Oct 3;54(10):6489-501. doi: 10.1167/iovs.13-12374.

PMID:
23982842
50.

Standardised disturbance of the optical coherence tomography signal has varying effects on the scan quality assessment when comparing four devices.

Kok PH, van Dijk HW, Stehouwer M, van den Berg TJ, Schlingemann RO, Verbraak FD.

Br J Ophthalmol. 2013 Nov;97(11):1484-5. doi: 10.1136/bjophthalmol-2013-303849. Epub 2013 Aug 21. No abstract available.

PMID:
23966374

Supplemental Content

Loading ...
Support Center